Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN 3 - vs. QW GLP-1)

Trial Profile

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN 3 - vs. QW GLP-1)

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Semaglutide (Primary) ; Exenatide
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms SUSTAIN-3
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 12 Oct 2017 Results of a post hoc analysis of SUSTAIN 2-5 trials presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 15 Sep 2017 Results of a post hoc analysis assessing efficacy and safety of semaglutide across background oral antidiabetics treatments using patient data from SUSTAIN 2-4 trials presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 15 Sep 2017 Results evaluated the efficacy and safety of semaglutide vs comparators in elderly ( greater than or equal to 65 years old) and non-elderly (less than 65 years old) subjects with Type-2-diabetes-mellitus across SUSTAIN 1-5 trials presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top